1.Device Closure or Antithrombotic Therapy After Cryptogenic Stroke in Elderly Patients With a High-Risk Patent Foramen Ovale
Pil Hyung LEE ; Jung-Sun KIM ; Jae-Kwan SONG ; Sun U. KWON ; Bum Joon KIM ; Ji Sung LEE ; Byung Joo SUN ; Jong Shin WOO ; Soe Hee ANN ; Jung-Won SUH ; Jun Yup KIM ; Kyusup LEE ; Sang Yeub LEE ; Ran HEO ; Soo JEONG ; Jeong Yoon JANG ; Jang-Whan BAE ; Young Dae KIM ; Sung Hyuk HEO ; Jong S. KIM
Journal of Stroke 2024;26(2):242-251
Background:
and Purpose In young patients (aged 18–60 years) with patent foramen ovale (PFO)- associated stroke, percutaneous closure has been found to be useful for preventing recurrent ischemic stroke or transient ischemic attack (TIA). However, it remains unknown whether PFO closure is also beneficial in older patients.
Methods:
Patients aged ≥60 years who had a cryptogenic stroke and PFO from ten hospitals in South Korea were included. The effect of PFO closure plus medical therapy over medical therapy alone was assessed by a propensity-score matching method in the overall cohort and in those with a high-risk PFO, characterized by the presence of an atrial septal aneurysm or a large shunt.
Results:
Out of the 437 patients (mean age, 68.1), 303 (69%) had a high-risk PFO and 161 (37%) patients underwent PFO closure. Over a median follow-up of 3.9 years, recurrent ischemic stroke or TIA developed in 64 (14.6%) patients. In the propensity score-matched cohort of the overall patients (130 pairs), PFO closure was associated with a significantly lower risk of a composite of ischemic stroke or TIA (hazard ratio [HR]: 0.45; 95% confidence interval [CI]: 0.24–0.84; P=0.012), but not for ischemic stroke. In a subgroup analysis of confined to the high-risk PFO patients (116 pairs), PFO closure was associated with significantly lower risks of both the composite of ischemic stroke or TIA (HR: 0.40; 95% CI: 0.21–0.77; P=0.006) and ischemic stroke (HR: 0.47; 95% CI: 0.23–0.95; P=0.035).
Conclusion
Elderly patients with cryptogenic stroke and PFO have a high recurrence rate of ischemic stroke or TIA, which may be significantly reduced by device closure.
2.Effect of abatacept versus csDMARDs on rheumatoid arthritis-associated interstitial lung disease
Kyung-Ann LEE ; Bo Young KIM ; Sung Soo KIM ; Yun Hong CHEON ; Sang-Il LEE ; Sang-Hyon KIM ; Jae Hyun JUNG ; Geun-Tae KIM ; Jin-Wuk HUR ; Myeung-Su LEE ; Yun Sung KIM ; Seung-Jae HONG ; Suyeon PARK ; Hyun-Sook KIM
The Korean Journal of Internal Medicine 2024;39(5):855-864
Background/Aims:
To compare the effects of abatacept and conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) on the progression and development of rheumatoid arthritis-associated interstitial lung disease (RA-ILD).
Methods:
This multi-center retrospective study included RA patients receiving abatacept or csDMARDs who underwent at least two pulmonary function tests and/or chest high-resolution computed tomography (HRCT). We compared the following outcomes between the groups: progression of RA-ILD, development of new ILD in RA patients without ILD at baseline, 28-joint Disease Activity Score with the erythrocyte sedimentation rate (DAS28-ESR), and safety. Longitudinal changes were compared between the groups by using a generalized estimating equation.
Results:
The study included 123 patients who were treated with abatacept (n = 59) or csDMARDs (n = 64). Nineteen (32.2%) and 38 (59.4%) patients treated with abatacept and csDMARDs, respectively, presented with RA-ILD at baseline. Newly developed ILD occurred in one patient receiving triple csDMARDs for 32 months. Among patients with RA-ILD at baseline, ILD progressed in 21.1% of cases treated with abatacept and 34.2% of cases treated with csDMARDs during a median 21-month follow-up. Longitudinal changes in forced vital capacity and diffusing capacity for carbon monoxide were comparable between the two groups. However, the abatacept group showed a more significant decrease in DAS28-ESR and glucocorticoid doses than csDMARDs group during the follow-up. The safety of both regimens was comparable.
Conclusions
Abatacept and csDMARDs showed comparable effects on the development and stabilization of RA-ILD. Nevertheless, compared to csDMARDs, abatacept demonstrated a significant improvement in disease activity and led to reduced glucocorticoid use.
3.Prediction of the 10-year risk of atherosclerotic cardiovascular disease in the Korean population
Sangwoo PARK ; Yong-Giun KIM ; Soe Hee ANN ; Young-Rak CHO ; Shin-Jae KIM ; Seungbong HAN ; Gyung-Min PARK
Epidemiology and Health 2023;45(1):e2023052-
OBJECTIVES:
Proper risk assessment is important for the primary prevention of atherosclerotic cardiovascular disease (ASCVD). However, no validated risk prediction tools are currently in use in Korea. This study sought to develop a 10-year risk prediction model for incident ASCVD.
METHODS:
Using the National Sample Cohort of Korea, 325,934 subjects aged 20-80 years without previous ASCVD were enrolled. ASCVD was defined as a composite of cardiovascular death, myocardial infarction, and stroke. The Korean atherosclerotic cardiovas cular disease risk prediction (K-CVD) model was developed separately for men and women using the development dataset and validated in the validation dataset. Furthermore, the model performance was compared with the Framingham risk score (FRS) and pooled cohort equation (PCE).
RESULTS:
Over 10 years of follow-up, 4,367 ASCVD events occurred in the overall population. The predictors of ASCVD included in the model were age, smoking status, diabetes, systolic blood pressure, lipid profiles, urine protein, and lipid-lowering and blood pressure-lowering treatment. The K-CVD model had good discrimination and strong calibration in the validation dataset (time-dependent area under the curve=0.846; 95% confidence interval, 0.828 to 0.864; calibration χ2=4.73, goodness-of-fit p=0.32). Compared with our model, both FRS and PCE showed worse calibration, overestimating ASCVD risk in the Korean population.
CONCLUSIONS
Through a nationwide cohort, we developed a model for 10-year ASCVD risk prediction in a contemporary Korean population. The K-CVD model showed excellent discrimination and calibration in Koreans. This population-based risk prediction tool would help to appropriately identify high-risk individuals and provide preventive interventions in the Korean population.
4.Effect of Bonebridge Implantation on Tinnitus in Patients With Asymmetric Hearing Loss or Single-Sided Deafness
Yeonji KIM ; Jae Sang HAN ; Celeste Ann CHUA ; Jae-Hyun SEO ; So Young PARK ; Shi Nae PARK
Korean Journal of Otolaryngology - Head and Neck Surgery 2022;65(10):580-586
Background and Objectives:
The objective of this study was to investigate the effect of an active transcutaneous bone conduction implant (BCI) of Bonebridge (MED-EL) on tinnitus patients with asymmetric hearing loss (AHL) or single-sided deafness (SSD).Subjects and Method Medical records and tinnitus questionnaires were reviewed retrospectively of patients with AHL or SSD, who received Bonebridge by a single surgeon at Seoul St. Mary’s Hospital from 2017 to 2021. Audiologic evaluation and tinnitus questionnaires were conducted before and after surgery.
Results:
Of the 17 patients, 8 patients had SSD and 9 patients had AHL, and 13 patients (76.47%) had tinnitus before surgery while 4 patients did not. No patient showed newly developed tinnitus after surgery. After implantation, three patients (23.08%) showed a complete resolution of tinnitus. All patients showed significant improvement in hearing level after surgery. The mean tinnitus handicap inventory (THI) score and visual analogue scale (VAS) score for effect on life showed a significant decrease after surgery, from 43.1±28.2 to 29.7±25.7 (p<0.05), and 4.7±2.9 to 3.2±3.3 (p<0.05), respectively. The mean THI scores of seven AHL patients and seven patients with tinnitus on the implanted ear were significantly decreased after implantation from 50.9±24.7 to 34.6±27.5 (p<0.05) and from 53.1±23.4 to 37.4±15.0 (p<0.05), respectively.
Conclusion
BCI seems to be effective in suppressing tinnitus in the patients with AHL but not with SSD. Along with directive counseling, sound therapy with Bonebridge can decrease tinnitus in some patients with AHL.
5.Impact of Diabetes Control on Subclinical Atherosclerosis: Analysis from Coronary Computed Tomographic Angiography Registry
Gyung-Min PARK ; Chang Hoon LEE ; Seung-Whan LEE ; Sung-Cheol YUN ; Young-Hak KIM ; Yong-Giun KIM ; Ki-Bum WON ; Soe Hee ANN ; Shin-Jae KIM ; Dong Hyun YANG ; Joon-Won KANG ; Tae-Hwan LIM ; Eun Hee KOH ; Woo Je LEE ; Min-Seon KIM ; Joong-Yeol PARK ; Hong-Kyu KIM ; Jaewon CHOE ; Sang-Gon LEE
Diabetes & Metabolism Journal 2020;44(3):470-479
There are limited data on the impact of diabetes control on the risk of subclinical coronary atherosclerosis. We analyzed 6,434 consecutive asymptomatic individuals without previous history of coronary artery disease who underwent coronary computed tomographic angiography (CCTA) (mean age, 53.7±7.6 years and 4,694 men [73.0%]). The degree and extent of subclinical coronary atherosclerosis were assessed by CCTA, and ≥50% diameter stenosis was defined as significant. A cardiac event was defined as a composite of all-cause death, myocardial infarction, unstable angina, or coronary revascularization. Study participants were categorized as normal ( Compared with normal individuals, there were no statistically significant differences in the risk of for any atherosclerotic plaque (odds ratio [OR], 1.16; 95% confidence interval [CI], 0.98 to 1.38; Asymptomatic uncontrolled diabetes was associated with significant subclinical coronary atherosclerosis with subsequent high risk for cardiac events.
6.A Prospective Study on Nutritional Status and Nutrient Intake of Hemodialysis Patients Based on Coexistence of Diabetes.
Ye Sung OH ; Jae Young ANN ; Mi Hyang KIM ; Sun Jung CHOE ; Jong Cheol JEONG
Journal of the Korean Dietetic Association 2017;23(1):1-13
It is well known that malnutrition is a predictor of mortality in hemodialysis patients. The number of diabetic nephropathy patients is increasing rapidly. This study aimed to investigate nutritional status and nutrient intake according to the presence of diabetes among hemodialysis patients. The nutritional intake and general characteristics of outpatients at Ajou University Hospital (24 with diabetes and 30 without diabetes) were investigated between July and September 2015. Patients' general data were collected, and nutritional status by Patient-Generated Subjective Global Assessment (PG-SGA) was evaluated. Nutrient intakes were assessed according to 3-day food records. There was no significant difference regarding body weight between the two groups. However, the non-diabetic group showed a better nutritional status by Patient-Generated Subjective Global Assessment (PG-SGA) (5.2±4.4 vs. 8.0±4.3 score, non-diabetics vs. diabetics, P<0.05). There was no difference in daily calorie intake (1,473.9±370.5 vs. 1,503.8±397.5 kcal) and protein intake (60.3±19.7 vs. 65.6±20.5 g) in those with diabetes. Intakes of vegetables protein, sodium, potassium, vitamin C, folic acid and fiber were significantly higher in the diabetic group compared to those of the non-diabetic group. There was no difference in daily nutrient intake between the hemodialysis weekday and weekend groups. The non-diabetic group had higher calorie and sodium intakes per meal in the hemodialysis weekday group, but the difference was not significant. Based on these results, intervention should be performed to improve nutritional status in consideration of diabetes and dietary patterns.
Ascorbic Acid
;
Body Weight
;
Diabetes Mellitus
;
Diabetic Nephropathies
;
Folic Acid
;
Humans
;
Malnutrition
;
Meals
;
Mortality
;
Nutritional Status*
;
Outpatients
;
Potassium
;
Prospective Studies*
;
Renal Dialysis*
;
Sodium
;
Vegetables
7.Transcriptome analyses of chronic traumatic encephalopathy show alterations in protein phosphatase expression associated with tauopathy.
Jeong Sun SEO ; Seungbok LEE ; Jong Yeon SHIN ; Yu Jin HWANG ; Hyesun CHO ; Seong Keun YOO ; Yunha KIM ; Sungsu LIM ; Yun Kyung KIM ; Eun Mi HWANG ; Su Hyun KIM ; Chong Hyun KIM ; Seung Jae HYEON ; Ji Young YUN ; Jihye KIM ; Yona KIM ; Victor E ALVAREZ ; Thor D STEIN ; Junghee LEE ; Dong Jin KIM ; Jong Il KIM ; Neil W KOWALL ; Hoon RYU ; Ann C MCKEE
Experimental & Molecular Medicine 2017;49(5):e333-
Chronic traumatic encephalopathy (CTE) is a progressive neurodegenerative disorder that is associated with repetitive head injury and has distinctive neuropathological features that differentiate this disease from other neurodegenerative diseases. Intraneuronal tau aggregates, although they occur in different patterns, are diagnostic neuropathological features of CTE, but the precise mechanism of tauopathy is not known in CTE. We performed whole RNA sequencing analysis of post-mortem brain tissue from patients with CTE and compared the results to normal controls to determine the transcriptome signature changes associated with CTE. The results showed that the genes related to the MAP kinase and calcium-signaling pathways were significantly downregulated in CTE. The altered expression of protein phosphatases (PPs) in these networks further suggested that the tauopathy observed in CTE involves common pathological mechanisms similar to Alzheimer's disease (AD). Using cell lines and animal models, we also showed that reduced PPP3CA/PP2B phosphatase activity is directly associated with increases in phosphorylated (p)-tau proteins. These findings provide important insights into PP-dependent neurodegeneration and may lead to novel therapeutic approaches to reduce the tauopathy associated with CTE.
Alzheimer Disease
;
Brain
;
Brain Injury, Chronic*
;
Cell Line
;
Craniocerebral Trauma
;
Gene Expression Profiling*
;
Humans
;
Models, Animal
;
Neurodegenerative Diseases
;
Phosphoprotein Phosphatases
;
Phosphotransferases
;
Sequence Analysis, RNA
;
Tauopathies*
;
Transcriptome*
8.Kawasaki Disease with Fever and Cervical Lymphadenopathy as the Sole Initial Presentation.
Woo Young JUN ; Yu Kyung ANN ; Ja Yeong KIM ; Jae Sung SON ; Soo Jin KIM ; Hyun Suk YANG ; Sun Hwan BAE ; Sochung CHUNG ; Kyo Sun KIM
Korean Circulation Journal 2017;47(1):107-114
BACKGROUND AND OBJECTIVES: Some patients with Kawasaki disease (KD) present with fever and cervical lymphadenopathy alone. The purpose of this study was to characterize the clinical features of these unusual KD patients and determine whether this is a severe form of KD associated with increased risks of intravenous immunoglobulin (IVIG) resistance and coronary artery lesions (CALs). SUBJECTS AND METHODS: A total of 146 children with KD were reviewed retrospectively, and classified into two groups according to initial clinical features. Those presenting with only fever and cervical lymphadenopathy (LKD) were classified as LKD patients. Other-KD patients included all except the LKD patients. RESULTS: Among 146 KD patients, 13 (8.9%) were classified as LKD patients. The LKD patients were significantly older and admitted earlier. The duration between fever onset and KD diagnosis was significantly longer in the LKD patients (5.9 days vs. 4.9 days, p=0.023). The frequency of IVIG resistance was not different between the two groups., In the LKD patients, the incidence of CALs was significantly higher in the acute phase, and without significant difference in the convalescent phase. The percentage of neutrophils and C-reactive protein, albumin, and total bilirubin levels were significantly higher in LKD patients. CONCLUSION: Even though LKD patients were older, admitted earlier, and had higher inflammatory marker levels, they did not have a greater risk of CALs or IVIG resistance. However, echocardiography may be helpful in the acute stage if patients have only fever and cervical lymphadenopathy and are unresponsive to empirical antibiotics.
Anti-Bacterial Agents
;
Bilirubin
;
C-Reactive Protein
;
Child
;
Coronary Vessels
;
Diagnosis
;
Echocardiography
;
Fever*
;
Humans
;
Immunoglobulins
;
Immunoglobulins, Intravenous
;
Incidence
;
Lymphatic Diseases*
;
Mucocutaneous Lymph Node Syndrome*
;
Neck
;
Neutrophils
;
Retrospective Studies
9.Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for patient with leptomeningeal metastasis of epidermal growth factor receptor mutant non-small cell lung cancer.
Jong Sik LEE ; Kyung Ann LEE ; Kang Hoon LEE ; Sun Young MOON ; In Ae KIM ; Sung Jin JEON ; Jae Ki MIN ; Hee Joung KIM ; Kye Young LEE
Yeungnam University Journal of Medicine 2016;33(1):64-67
We report on a 64-year-old man with leptomeningeal metastasis (LM) from an epidermal growth factor receptor (EGFR)-mutated adenocarcinoma of the lung. He was treated with paclitaxel, cisplatin. After completion of chemotherapy, he complained of headache, nausea, and vomiting. EGFR-mutated tumor cells were identified from the cerebrospinal fluid (CSF). Second-line therapy with gefitinib, methotrexate was started. After receiving gefitinib for 4 weeks, he had no more headaches or vomiting. Eleven months after initiation of gefitinib, he developed headache and nausea. Chest computed tomography showed aggravation of bone metastasis. Third-line therapy was started with gemcitabine and carboplatin. Two weeks later, he experienced disorientation. After a fourth relapse within the central nervous system, the therapy was switched to erlotinib and significant improvement of LM was achieved. This case shows that LM can be diagnosed by detecting EGFR mutation in CSF and EGFR tyrosine kinase inhibitors are effective for LM from EGFR mutant non-small cell lung cancer.
Adenocarcinoma
;
Carboplatin
;
Carcinoma, Non-Small-Cell Lung
;
Central Nervous System
;
Cerebrospinal Fluid
;
Cisplatin
;
Drug Therapy
;
Epidermal Growth Factor*
;
Erlotinib Hydrochloride
;
Headache
;
Humans
;
Lung Neoplasms*
;
Lung*
;
Methotrexate
;
Middle Aged
;
Nausea
;
Neoplasm Metastasis*
;
Paclitaxel
;
Phosphotransferases*
;
Protein-Tyrosine Kinases
;
Receptor, Epidermal Growth Factor*
;
Recurrence
;
Thorax
;
Vomiting
10.Risk Factors for Mortality in Patients with Serratia marcescens Bacteremia.
Sun Bean KIM ; Yong Duk JEON ; Jung Ho KIM ; Jae Kyoung KIM ; Hea Won ANN ; Heun CHOI ; Min Hyung KIM ; Je Eun SONG ; Jin Young AHN ; Su Jin JEONG ; Nam Su KU ; Sang Hoon HAN ; Jun Yong CHOI ; Young Goo SONG ; June Myung KIM
Yonsei Medical Journal 2015;56(2):348-354
PURPOSE: Over the last 30 years, Serratia marcescens (S. marcescens) has emerged as an important pathogen, and a common cause of nosocomial infections. The aim of this study was to identify risk factors associated with mortality in patients with S. marcescens bacteremia. MATERIALS AND METHODS: We performed a retrospective cohort study of 98 patients who had one or more blood cultures positive for S. marcescens between January 2006 and December 2012 in a tertiary care hospital in Seoul, South Korea. Multiple risk factors were compared with association with 28-day all-cause mortality. RESULTS: The 28-day mortality was 22.4% (22/98 episodes). In a univariate analysis, the onset of bacteremia during the intensive care unit stay (p=0.020), serum albumin level (p=0.011), serum C-reactive protein level (p=0.041), presence of indwelling urinary catheter (p=0.023), and Sequential Oran Failure Assessment (SOFA) score at the onset of bacteremia (p<0.001) were significantly different between patients in the fatal and non-fatal groups. In a multivariate analysis, lower serum albumin level and an elevated SOFA score were independently associated with 28-day mortality [adjusted odds ratio (OR) 0.206, 95% confidential interval (CI) 0.044-0.960, p=0.040, and adjusted OR 1.474, 95% CI 1.200-1.810, p<0.001, respectively]. CONCLUSION: Lower serum albumin level and an elevated SOFA score were significantly associated with adverse outcomes in patients with S. marcescens bacteremia.
Adult
;
Aged
;
Aged, 80 and over
;
Anti-Bacterial Agents/therapeutic use
;
Bacteremia/drug therapy/microbiology/*mortality
;
Cross Infection/mortality
;
Female
;
Humans
;
Intensive Care Units
;
Male
;
Middle Aged
;
Multiple Organ Failure
;
Republic of Korea/epidemiology
;
Retrospective Studies
;
Risk Factors
;
Serratia Infections/diagnosis/drug therapy/*mortality
;
Serratia marcescens/drug effects/*isolation & purification
;
Severity of Illness Index
;
Survival Rate
;
Time Factors
;
Treatment Outcome

Result Analysis
Print
Save
E-mail